Announced Date: 2024-06-14 (June 14, 2024)
Asset Name: Olverembatinib
Licensor: Ascentage Pharma (China)
Licensee (Buyer): Takeda (Japan)
.
Asset Modality: Small Molecule, Oral
Asset Target: third-generation BCR-ABL tyrosine kinase inhibitor (TKI)
Potential Indication: Chronic myeloid leukemia (CML) and other hematological cancers
Current Stage: Olverembatinib is currently approved and marketed in China.
.
Scope of Authority:
The option would allow Takeda to license global rights to develop and commercialize olverembatinib in all territories outside of mainland China, Hong Kong, Macau, Taiwan and Russia.
.
Deal Detail:
Upfront payment of $100 million,
Milestone payments.
.
Link:
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Takeda Signs Option Agreement with Ascentage Pharma for Olverembatinib
